GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Hepatitis/Chronic Hepatitis B: Even Moderate Alcohol Intake May Add to HCC Risk: CGH | September 2026
7

Chronic Hepatitis B: Even Moderate Alcohol Intake May Add to HCC Risk: CGH | September 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2026

What Did the Study Find?

This two-center cohort followed 1,010 patients with chronic hepatitis B, with 129 developing hepatocellular carcinoma (HCC) during 3,684 person-years of follow-up.

HCC risk increased in a dose-dependent manner with alcohol consumption.

Every additional 100 g of alcohol/week was associated with a 33% higher HCC risk.

High alcohol intake was associated with approximately a 4-fold higher risk compared with low intake.

The association persisted after multivariable adjustment.

Importantly, increased risk was seen in both cirrhotic and non-cirrhotic patients.

The relationship remained evident across HBV DNA, HBeAg, aMAP and mPAGE-B risk strata.

Why Does It Matter?

HCC risk in chronic HBV reflects more than viral activity and fibrosis. Alcohol may provide an important additional and potentially modifiable risk factor, even before cirrhosis develops.

GastroAGI Takeaway

Alcohol history should be part of routine HCC-risk assessment in every patient with chronic HBV—not only those with cirrhosis. The dose-response signal strengthens the rationale for alcohol reduction or abstinence counselling, although these observational data demonstrate association and cannot establish causality.

Related Q&A

08

EASL–AASLD PBC Consensus 2026: Journal of Hepatology | September 2026 | EASL–AASLD Delphi Consensus

ALP + bilirubin remain the core biochemical treatment targets Both ALP and total bilirubin at 12 months consistently predict clinically important outcomes in PBC, including decompensation, transplantation and...

09

HBsAg Negative Does Not Always Mean HBV Negative: Nature Reviews Gastroenterology & Hepatology | September 2026

What Does the Review Clarify? This major review provides a practical framework for understanding and investigating occult hepatitis B virus infection (OBI). OBI means replication-competent HBV DNA despite...

10

New PBC Consensus Makes Liver Stiffness Central to Follow-up: ÖGGH | September 2026

Introduction: PBC management is moving beyond simply starting UDCA and assessing response after one year. The new Austrian consensus emphasizes earlier biochemical assessment, more ambitious treatment targets, second-line...

11

MRCP Screening Reveals Unsuspected PSC in Nearly 1 in 10 Newly Diagnosed IBD Patients: CGH | September 2026

Introduction: PSC is strongly associated with IBD, but screening is usually prompted by abnormal liver biochemistry. The Copenhagen IBD inception cohort examined how often systematic MRCP at IBD...

12

MYR301: What Happens When Bulevirtide Is Stopped in Chronic Hepatitis D: Journal of Hepatology | September 2026 | Phase III MYR301 Trial

Introduction: Bulevirtide has transformed treatment of chronic hepatitis D (HDV), but the optimal treatment duration remains uncertain. Final MYR301 data address a crucial practical question: can treatment be...

13

FibroScan Liver Stiffness Strongly Predicts Outcomes in PSC: Gastroenterology | August 2026

Introduction: Risk stratification in primary sclerosing cholangitis (PSC) remains challenging because conventional biochemical markers do not reliably predict disease progression. The international FICUS cohort evaluated whether VCTE-based liver...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer